SIMILAR EFFICACY AND SAFETY OF BIOSIMILAR CANDIDATE BI 695501 AND ADALIMUMAB ORIGINATOR REFERENCE PRODUCT IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS: 24 WEEK RESULTS FROM A PHASE III CLINICAL STUDY (VOLTAIRE®-RA)

被引：2
|
作者：
Cohen, S. [1 ]
Alonso-Ruiz, A. [2 ]
Klimiuk, P. A. [3 ,4 ]
Lee, E. [5 ]
Peter, N. [6 ]
Sonderegger, I. [6 ]
Assudani, D. [6 ]
机构：
[1] Metroplex Clin Res Ctr, Dallas, TX USA
[2] Hosp Cruces, Baracaldo, Spain
[3] Med Univ Bialystok, Bialystok, Poland
[4] Gabinet InternistycznoReumatol, Bialystok, Poland
[5] Inland Rheumatol, Upland, CA USA
[6] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.3405
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0189
引用
收藏
页码：553 / 553
页数：1
相关论文
共 50 条
  • [1] Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
    Cohen, Stanley B.
    Alonso-Ruiz, Alberto
    Klimiuk, Piotr A.
    Lee, Eric C.
    Peter, Nuala
    Sonderegger, Ivo
    Assudani, Deepak
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (06) : 914 - 921
  • [2] Biosimilar Candidate BI 695501 and Adalimumab Reference Product Have Similar Efficacy and Safety in Patients with Moderately-to-Severely Active Rheumatoid Arthritis (RA): 1-Year Results from a Phase III Study
    Cohen, Stanley B.
    Alonso-Ruiz, Alberto
    Klimiuk, Piotr A.
    Lee, Eric
    Peter, Nuala
    Czeloth, Niklas
    Jayadeva, Girish
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [3] Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study
    Menter, Alan
    Arenberger, Petr
    Balser, Sigrid
    Beissert, Stefan
    Cauthen, Ashley
    Czeloth, Niklas
    Soung, Jennifer
    Jazayeri, Sasha
    Weisenseel, Peter
    Jayadeva, Girish
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (01) : 87 - 96
  • [4] Biosimilar BI 695501 and Adalimumab Reference Product (RP) Have Similar Efficacy and Safety in Patients (pts) with Moderately-to-Severely Active Rheumatoid Arthritis (RA): Long-Term Results from a Phase IIIb Extension Study (VOLTAIRE®-RAext)
    Cohen, Stanley
    Czeloth, Niklas
    Lees, Eric
    Klimiuk, Piotr A.
    Peter, Nuala
    Jayadeva, Girish
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [5] EFFICACY AND SAFETY RESULTS OF A PHASE III STUDY COMPARING FKB327, AN ADALIMUMAB BIOSIMILAR, WITH THE ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
    Alten, R.
    Glover, J.
    Matsunaga, N.
    Chisholm, D.
    Genovese, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 59 - 59
  • [6] Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext)
    Cohen, Stanley B.
    Czeloth, Niklas
    Lee, Eric
    Klimiuk, Piotr A.
    Peter, Nuala
    Jayadeva, Girish
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (10) : 1097 - 1105
  • [7] Comparison of the efficacy and safety of LBAL, a candidate adalimumab biosimilar, and adalimumab reference product in patients with active rheumatoid arthritis inadequately responding to methotrexate: A 52-week phase III randomised study
    Matsuno, H.
    Kang, Y. M.
    Okada, M.
    Lee, S-, I
    Park, S-H
    Sheen, D. H.
    Sato, M.
    Hagino, A.
    Lee, J.
    Shin, S.
    Song, Y. W.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (05) : 1025 - 1033
  • [8] BI 695501 DEMONSTRATES SIMILAR EFFICACY AND COMPARABLE SAFETY TO ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH ACTIVE CROHN'S DISEASE: FINAL ANALYSIS OF THE PHASE III VOLTAIRE-CD STUDY
    Hanauer, Stephen B.
    Schreiber, Stefan
    Balser, Sigrid E.
    Brockstedt, Ekkehard
    Moschetti, Viktoria
    Liedert, Bernd J.
    GASTROENTEROLOGY, 2020, 158 (06) : S1192 - S1193
  • [9] Biosimilar BI 695501 demonstrates clinical equivalence to adalimumab reference product in patients with moderate to severe chronic plaque psoriasis through 24 weeks
    Menter, Alan
    Arenberger, Petr
    Balser, Sigrid
    Beissert, Stefan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB5 - AB5
  • [10] IMPACT OF ANTI-DRUG ANTIBODIES ON EFFICACY AND SAFETY UP TO WEEK 24 FROM A PHASE III STUDY COMPARING SB5 (AN ADALIMUMAB BIOSIMILAR) WITH ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY
    Genovese, M. C.
    Weinblatt, M.
    Keystone, E.
    Baranauskaite, A.
    Cheong, S. Y.
    Ghil, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 234 - 234
12345